News
CDXC
--
0.00%
--
Trade Alert: Hoi Shuen Chau At ChromaDex Corporation (NASDAQ:CDXC), Has Just Spent US$52k Buying A Small Number of Shares
Whilst it may not be a huge deal, we thought it was good to see that Hoi Shuen Chau, who is a company insider, recently...
Simply Wall St. · 3d ago
ChromaDex Establishes Joint Venture For Tru Niagen Distribution In China
Benzinga · 5d ago
ChromaDex stock gains postmarket on JV to distribute supplement in China
ChromaDex (NASDAQ:CDXC) stock jumped ~16% postmarket on Thursday after the firm said it will set up a joint venture to distribute Tru Niagen supplement in China. The other JV partners are Crystal
Seekingalpha · 5d ago
ChromaDex Announces Agreement To Launch Commercial Joint Venture In Mainland China
ChromaDex Corp. (NASDAQ:CDXC) ("the Company") a global bioscience company dedicated to healthy aging, today announced it has entered into an agreement (the "JV Agreement") to establish a joint venture
Benzinga · 5d ago
ChromaDex Forming Joint Venture to Sell Tru Niagen Supplement in China; Shares Jump Almost 14% in After-Hours Trade
MT Newswires · 5d ago
How Much Of ChromaDex Corporation (NASDAQ:CDXC) Do Insiders Own?
A look at the shareholders of ChromaDex Corporation ( NASDAQ:CDXC ) can tell us which group is most powerful. Insiders...
Simply Wall St. · 05/17 12:27
ChromaDex Wins International 2022 European NutraIngredients Award for Developing the Science Behind Niagen®
LOS ANGELES, May 17, 2022--ChromaDex Corp. (NASDAQ:CDXC) announced today that NutraIngredients, a leading news source for the nutrition industry, recently honored the ChromaDex External Research Program (CERPTM) with a 2022 European NutraIngredients Award ...
Business Wire · 05/17 10:34
Where ChromaDex Stands With Analysts
Within the last quarter, ChromaDex (NASDAQ:CDXC) has observed the following analyst ratings:
Benzinga · 05/13 20:31
--B. Riley Lowers ChromaDex's Price Target to $6 from $8 on Lower Multiple, Keeps Buy Rating
MT Newswires · 05/13 09:53
ChromaDex (CDXC) Reports Q1 Loss, Misses Revenue Estimates
ChromaDex (CDXC) delivered earnings and revenue surprises of -22.22% and 0.90%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/12 21:35
Recap: ChromaDex Q1 Earnings
ChromaDex (NASDAQ:CDXC) reported its Q1 earnings results on Thursday, May 12, 2022 at 04:01 PM. Here's what investors need to know about the announcement. Earnings ChromaDex missed estimated earnings by 22.22%, reporting an EPS of $-0.11 versus an estimate...
Benzinga · 05/12 21:05
ChromaDex Q1 EPS $(0.11) Misses $(0.09) Estimate, Sales $17.30M Beat $17.23M Estimate
ChromaDex (NASDAQ:CDXC) reported quarterly losses of $(0.11) per share which missed the analyst consensus estimate of $(0.09) by 22.22 percent. This is a 8.33 percent increase over losses of $(0.12) per share from the
Benzinga · 05/12 20:31
ChromaDex GAAP EPS of -$0.11 misses by $0.02, revenue of $17.26M misses by $0.26M
ChromaDex press release (NASDAQ:CDXC): Q1 GAAP EPS of -$0.11 misses by $0.02. Revenue of $17.26M (+17.6% Y/Y) misses by $0.26M. Looking forward, for the full year, the Company expects 15-20%
Seekingalpha · 05/12 20:06
-- Earnings Flash (CDXC) CHROMADEX CORPORATION Reports Q1 Revenue $17.3M, vs. Street Est of $17.5M
MT Newswires · 05/12 16:05
ChromaDex Q1 2022 Earnings Preview
ChromaDex (NASDAQ:CDXC) is scheduled to announce Q1 earnings results on Thursday, May 12th, after market close. The consensus EPS Estimate is -$0.09 (vs. -$0.12 last year) and the consensus Revenue Estimate
Seekingalpha · 05/11 21:35
ADC Therapeutics SA (ADCT) Reports Q1 Loss, Tops Revenue Estimates
ADC Therapeutics SA (ADCT) delivered earnings and revenue surprises of 52.63% and 55.50%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/09 12:25
Repare Therapeutics Inc. (RPTX) Reports Q1 Loss, Misses Revenue Estimates
Repare Therapeutics Inc. (RPTX) delivered earnings and revenue surprises of 6.74% and 80.87%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?
Zacks · 05/06 00:35
ChromaDex (CDXC) May Report Negative Earnings: Know the Trend Ahead of Q1 Release
ChromaDex (CDXC) doesn't possess the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.
Zacks · 04/28 19:02
ChromaDex Appoints Ann Cohen and Kristin Patrick to its Board of Directors
LOS ANGELES, April 22, 2022--ChromaDex Corp. (NASDAQ: CDXC) today announced that it has appointed two new members to its Board of Directors: Kristin Patrick, Executive Vice President and Chief Marketing Officer of Claire's Inc., and Ann Cohen, Executive Vi...
Business Wire · 04/22 10:34
HC Wainwright Adjusts ChromaDex's Price Target to $8 From $12, Keeps Buy Rating
MT Newswires · 04/18 07:04
Webull provides a variety of real-time CDXC stock news. You can receive the latest news about Chromadex Corp through multiple platforms. This information may help you make smarter investment decisions.
About CDXC
ChromaDex Corp. is a global bioscience company, which is engaged in research on nicotinamide adenine dinucleotide (NAD+), levels of which decline with age. NAD+ is a coenzyme and a regulator of cellular metabolism. It operates through three segments: Consumer products, Ingredients, and Analytical reference standards and services segment. The Consumer products segment provides finished dietary supplement products that contain the ingredients directly to consumers as well as to distributors. The Ingredients segment develops and commercializes ingredient technologies and supplies these ingredients as raw materials to the manufacturers of consumer products. The Analytical reference standards and services segment supplies phytochemical reference standards and other research and development services. Its ingredients include Tru Niagen and Immulina. The Tru Niagen is a form nicotinamide riboside (NR). NR is a member of the vitamin B3 family. Immulina is a spirulina extract.